Stock Market Reviews

VCYT (Veracyte, Inc.) News

Get the latest news, insights, and market updates on VCYT (Veracyte, Inc.). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Is Veracyte, Inc. (NASDAQ:VCYT) Trading At A 30% Discount?
  Key Insights Using the 2 Stage Free Cash Flow to Equity, Veracyte fair value estimate is US$60.08 Veracyte's US$42.21...
  Dec 18, 2025 - $VCYT
• Beat the Market the Zacks Way: Veracyte, Las Vegas Sands, 3M in Focus
  Veracyte, Las Vegas Sands and 3M shine as Zacks spotlights standout stock gains and portfolio wins amid shifting market sentiment.
  Dec 8, 2025 - $VCYT
• EHC Opens New Lake Worth Rehab Hospital to Meet Rising Demand
  Encompass Health expands its Florida presence with a new Lake Worth rehab hospital, adding 50 beds and advanced therapy services to meet rising demand.
  Dec 3, 2025 - $VCYT
• 3 Stocks That May Be Undervalued By The Market In November 2025
  In November 2025, the United States stock market has experienced significant volatility, with major indices like the Nasdaq and S&P 500 posting losses despite initial gains driven by strong earnings from companies such as Nvidia. Amidst this turbulence, investors may find opportunities in stocks that appear undervalued by the market; these stocks often possess solid fundamentals that could be overlooked during broader market downturns.
  Nov 21, 2025 - $VCYT
• US High Growth Tech Stocks with Promising Potential
  As the U.S. stock market experiences a downturn with the S&P 500 closing lower for four consecutive sessions and tech stocks under pressure, investors are keenly observing key earnings reports and economic indicators that could impact future performance. In this environment, identifying high growth tech stocks with strong fundamentals and innovative potential becomes crucial for navigating market volatility effectively.
  Nov 19, 2025 - $VCYT
• We Think Veracyte's (NASDAQ:VCYT) Robust Earnings Are Conservative
  When companies post strong earnings, the stock generally performs well, just like Veracyte, Inc.'s ( NASDAQ:VCYT...
  Nov 12, 2025 - $VCYT
• VCYT Stock Gains on Q3 Earnings and Revenue Beat, '25 View Up
  Veracyte surges 27.5% after Q3 earnings and revenues beat estimates, driven by strong Decipher and Afirma test growth.
  Nov 11, 2025 - $VCYT
• Veracyte (VCYT) Turns Profitable, But Significant $27M Loss Challenges Bullish Narratives
  Veracyte (VCYT) recently moved into profitability, with its net profit margin turning positive even as a significant, non-recurring loss of $27.0 million affected the latest twelve-month results to September 30, 2025. Over the past five years, the company’s annual earnings growth stood at 29.3%. Looking ahead, analysts expect earnings to rise at a robust 26.6% per year, outpacing the broader US market’s 16% growth forecast. Revenue is projected to grow at 10.1% per year. For investors, the...
  Nov 6, 2025 - $VCYT
• Veracyte to Participate in Upcoming Investor Conferences
  SOUTH SAN FRANCISCO, Calif., November 06, 2025--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences.
  Nov 6, 2025 - $VCYT
• Veracyte Inc (VCYT) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
  Veracyte Inc (VCYT) reports a 14% revenue increase and record EBITDA margin, while navigating competitive pressures and strategic investments.
  Nov 5, 2025 - $VCYT